|
Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
Manuel David Gil-Sierra1, Maria Del Pilar Briceño-Casado2, Francisco Javier Julia-Luna2, Maria Dolores Martinez-Moya3
1 Department of Pharmacy, Hospital Universitario Puerto Real, Cadiz; Department of Pharmacology, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain
2 Department of Pharmacy, Hospital General Nuestra Señora del Prado, Toledo, Spain
3 Department of Hematology, Hospital General Nuestra Señora del Prado, Toledo, Spain
Correspondence Address:
Manuel David Gil-Sierra
Calle Playa de Bolonia No 10, Cádiz-11406
Spain
Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by short follow-up of patients with poor prognoses. Cases with long follow-ups could provide additional information about BLMF. This case reports a patient with MM treated with BLMF who had received nine previous lines of therapy with a follow-up of 11 months. No complete response was obtained. However, no disease progression was observed and the patient was still alive at the end of this work. BLMF showed manageable adverse effects. Our patient presented advanced disease, good functional status at the beginning of BLMF treatment, and elevated levels of lactate dehydrogenase during BLMF therapy. The influence of these last two factors was not evaluated in clinical trials. This relationship should be assessed more deeply in future studies.
How to cite this article:
Gil-Sierra MD, Briceño-Casado MD, Julia-Luna FJ, Martinez-Moya MD. Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.Indian J Pharmacol 2022;54:373-376
|
How to cite this URL:
Gil-Sierra MD, Briceño-Casado MD, Julia-Luna FJ, Martinez-Moya MD. Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma. Indian J Pharmacol [serial online] 2022 [cited 2023 Mar 30 ];54:373-376
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2022;volume=54;issue=5;spage=373;epage=376;aulast=Gil-Sierra;type=0 |
|
